Ligand Pharmaceuticals | LGND - Loan Capital


Ligand Pharmaceuticals reported $445.49M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Agenus USD 169.66M 146.06M Dec/2025
Amgen USD 50B 2.43B Dec/2025
Anika Therapeutics USD 25M 25M Sep/2020
Arrowhead Research USD 538.1M 323.22M Dec/2025
Baxter International USD 9.47B 726M Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
Enviri Corporation USD 1.53B 30.27M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Karyopharm Therapeutics USD -0.93 0.67 Dec/2024
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
MacroGenics USD 70M 256K Dec/2025
Merck USD 39.97B 6B Sep/2025
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 0 0 Mar/2025